Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 4.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 438,304 shares of the biopharmaceutical company's stock after purchasing an additional 19,324 shares during the period. Charles Schwab Investment Management Inc. owned 0.35% of Alnylam Pharmaceuticals worth $83,896,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of ALNY. Commonwealth Equity Services LLC boosted its position in shares of Alnylam Pharmaceuticals by 9.1% in the third quarter. Commonwealth Equity Services LLC now owns 4,372 shares of the biopharmaceutical company's stock valued at $774,000 after acquiring an additional 363 shares during the period. Raymond James & Associates boosted its position in shares of Alnylam Pharmaceuticals by 5.1% in the third quarter. Raymond James & Associates now owns 12,411 shares of the biopharmaceutical company's stock valued at $2,198,000 after acquiring an additional 598 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Alnylam Pharmaceuticals by 3.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 60,719 shares of the biopharmaceutical company's stock valued at $10,739,000 after acquiring an additional 2,268 shares during the period. Advisor Partners II LLC lifted its position in Alnylam Pharmaceuticals by 25.8% during the third quarter. Advisor Partners II LLC now owns 1,646 shares of the biopharmaceutical company's stock valued at $292,000 after purchasing an additional 338 shares during the last quarter. Finally, Assetmark Inc. lifted its position in Alnylam Pharmaceuticals by 19.3% during the third quarter. Assetmark Inc. now owns 5,778 shares of the biopharmaceutical company's stock valued at $1,023,000 after purchasing an additional 934 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock traded down $2.00 during mid-day trading on Tuesday, reaching $147.89. 604,169 shares of the stock traded hands, compared to its average volume of 736,827. The stock has a market capitalization of $18.71 billion, a PE ratio of -55.18 and a beta of 0.41. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $218.88. The business's 50-day moving average is $149.28 and its 200-day moving average is $164.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million for the quarter, compared to analysts' expectations of $428.01 million. The firm's revenue was up 54.8% compared to the same quarter last year. During the same quarter last year, the company posted ($1.40) EPS. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.77 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on ALNY shares. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. Morgan Stanley dropped their target price on shares of Alnylam Pharmaceuticals from $184.00 to $176.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 13th. Citigroup dropped their target price on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a "buy" rating for the company in a research report on Friday, February 16th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $165.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Finally, Wells Fargo & Company decreased their target price on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an "equal weight" rating on the stock in a research report on Friday, February 16th. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $216.19.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.